rs387906886
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_016219.5(MAN1B1):c.1000C>T(p.Arg334Cys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000229 in 1,614,132 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 13/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_016219.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MAN1B1 | NM_016219.5 | c.1000C>T | p.Arg334Cys | missense_variant | 7/13 | ENST00000371589.9 | NP_057303.2 | |
MAN1B1 | XM_006716945.5 | c.1000C>T | p.Arg334Cys | missense_variant | 7/12 | XP_006717008.1 | ||
MAN1B1 | NR_045720.2 | n.1015C>T | non_coding_transcript_exon_variant | 7/13 | ||||
MAN1B1 | NR_045721.2 | n.1146C>T | non_coding_transcript_exon_variant | 8/14 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MAN1B1 | ENST00000371589.9 | c.1000C>T | p.Arg334Cys | missense_variant | 7/13 | 1 | NM_016219.5 | ENSP00000360645.4 |
Frequencies
GnomAD3 genomes AF: 0.0000591 AC: 9AN: 152186Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000358 AC: 9AN: 251440Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135916
GnomAD4 exome AF: 0.0000192 AC: 28AN: 1461828Hom.: 0 Cov.: 32 AF XY: 0.0000179 AC XY: 13AN XY: 727216
GnomAD4 genome AF: 0.0000591 AC: 9AN: 152304Hom.: 0 Cov.: 33 AF XY: 0.0000269 AC XY: 2AN XY: 74460
ClinVar
Submissions by phenotype
Rafiq syndrome Pathogenic:2
Pathogenic, no assertion criteria provided | literature only | OMIM | Jul 15, 2011 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Mar 01, 2020 | Review of the variants reported in Reuter et al., 2017, PMID: 28097321: PM2,PM3_Strong,PP1_Strong,PP3, - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 29, 2022 | The c.1000C>T (p.R334C) alteration is located in exon 7 (coding exon 7) of the MAN1B1 gene. This alteration results from a C to T substitution at nucleotide position 1000, causing the arginine (R) at amino acid position 334 to be replaced by a cysteine (C). Based on data from gnomAD, the T allele has an overall frequency of <0.01% (10/282840) total alleles studied. The highest observed frequency was 0.02% (4/24956) of African alleles. This alteration has been identified in the homozygous or compound heterozygous state in multiple individuals with intellectual disability and/or other clinical presentations consistent with MAN1B1-related congenital disorder of glycosylation (CDG) type II (Rafiq, 2011; Najmabadi, 2011; Rymen, 2013; Van Scherpenzeel, 2014; Hoffjan, 2015). This amino acid position is highly conserved in available vertebrate species. Studies in HEK293 cells showed decreased expression of the variant protein and reduction in kinetic efficiency of the enzyme compared to wild type, while studies in patient derived fibroblasts indicated this alteration would lead to reduced protein expression, N-Glycan abnormalities, and altered Golgi morphology (Rafiq, 2011; Rymen, 2013). This alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as pathogenic. - |
See cases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University Hospital Muenster | Oct 18, 2021 | ACMG categories: PS5,PM1,PM2,PP3,PP5 - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 27, 2023 | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 27148587, 24566669, 34426522, 34791078, 34258140, 34162022, 36142510, 26279649, 21937992, 24348268, 29908352, 21763484) - |
MAN1B1-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 05, 2019 | The MAN1B1 c.1000C>T (p.Arg334Cys) missense variant has been reported in seven individuals from three families with autosomal recessive intellectual disability. Rafiq et al. (2011) identified the variant in a homozygous state in three affected siblings from a non-consanguineous Iranian family, Hoffjan et al. (2015) found the variant in a homozygous state in three affected siblings from a consanguineous Turkish family, and Balasubramanian et al. (2018) detected the variant in a compound heterozygous state with a frameshift variant in one affected individual of European descent. The variant was said to segregate with disease in the Iranian and Turkish families. The p.Arg334Cys variant has been further reported in a homozygous state in six individuals from five families with a diagnosis of congenital disorders of glycosylation (Rymen et al. 2013; Van Scherpenzeel et al. 2014; Gupta et al. 2016). The p.Arg334Cys variant was absent from 346 Iranian and German controls and is reported at a frequency of 0.000167 in the African population of the Genome Aggregation Database. Expression of wild type and p.Arg334Cys variant constructs in HEK293 cells showed that the variant protein was expressed and secreted at 20% of the wild type levels, with a reduction in the kinetic efficiency of the enzyme compared to wild type (Rafiq et al. 2011). Based on the collective evidence, the p.Arg334Cys variant is classified as pathogenic for MAN1B1-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at